Part I Molecular level 1. Molecular and cellular targets in the management of metabolic diseases and disorders: an overview 2. Redox biology, metabolic disorders and therapeutic opportunities 3. NADPH oxidase, obesity and metabolic syndrome: therapeutic opportunity 4. NAPDH oxidase and diabetes mellitus: therapeutic strategies 5. Targeting reactive carbonyls in metabolic disorders 6. Antioxidant supplementation and metabolic disorders 7. Modulation of the immune system as a pharmacological target in metabolic diseases Part II Subcellular and cellular levels 8.
Modulation of mitochondrial physiology in the prevention and management of metabolic disorders 9. Targeting autophagy in metabolic diseases 10. Endoplasmic reticulum as a pharmacological target in metabolic diseases II. Subsection: Organs as pharmacological targets in metabolic diseases and disorders 11. The gut-brain axis as a pharmacological target in metabolic diseases 12. Cardiomyopathy in metabolic diseases: pharmacological strategies 13. The cardio-renal-metabolic connection as a pharmacological target 14. Adipose tissue and metabolic diseases: a target for prevention and treatment of metabolic diseases 15.
Diabetic kidney disease: treatment and challenges 16. Fatty liver disease: a therapeutical approach 17. Pharmacologic intervention of nonalcoholic steatohepatitis and related cirrhosis Part III Subsection: Diabetes mellitus 18. Pharmacological management of diabetes mellitus complications Part IV Subsection: Obesity 19. Pharmacological targets in obesity 20. Diet, obesity, and methylglyoxal: therapeutic opportunities 21. Obesity-related dyslipidemia: pharmacological targets and opportunities Part V Subsection: Metabolic syndrome 22. Metabolic syndrome: pharmacological strategies and challenges 23.
Pharmacological targets in metabolic syndrome-related dyslipidemia 24. Therapeutic intervention in metabolic syndrome: present status and perspectives Part VI Subsection: Inborn errors of metabolism 25. Fatty acid oxidation disorders: a pharmacological approach 26. Pharmacological treatment of phenylketonuria 27. Pharmacological targets in inborn errors of metabolism in adult patients Part VII Subsection: Natural molecules and metabolic diseases and disorders 28. Polyphenols and obesity: molecular targets and therapeutic potential 29. Plant molecules and diabetes mellitus: prevention and management 30. Molecular targets in dyslipidemia: therapeutic potential of plant molecules 31.
Polyphenols and modulation of cholesterol metabolism 32. Polyphenols and the control of immunometabolism as a pharmacological target Part VIII Subsection: Microbiota and metabolic diseases and disorders 33. Microbiota, metabolic disorders and pharmacological opportunities 34. Plant extracts/molecules in obesity and the gut microbiota 35. Microbiome/microbiota and diabetes mellitus: pharmacological opportunities and challenges 36. Microbiome/microbiota and fatty liver disease: potential candidate for therapeutic intervention Part IX Subsection: Aging 37. Aging, metabolic disorders and the mitochondria: pharmacological opportunities Part X Subsection: Nanotechnology and metabolic diseases and disorders 38. Nanotechnology-related strategies for the prevention of metabolic syndrome Part XI Subsection: Metabolic diseases and disorders and the environment 39.
Environmental pollution and metabolic diseases: a pharmacological challenge Part XII Subsection: Diagnostic of metabolic diseases and disorders 40. Diagnostic techniques in metabolic diseases and disorders.